Background Cryptococcal meningitis is a leading cause of human immunodeficiency virus (HIV)–related
death in sub-Saharan Africa. Whether a treatment regimen that includes a …

Background Cryptococcal meningitis accounts for 20 to 25% of acquired immunodeficiency
syndrome–related deaths in Africa. Antiretroviral therapy (ART) is essential for survival; …

Background. Cryptococcal meningitis (CM) is a leading cause of death in individuals infected
with human immunodeficiency virus (HIV). Identifying factors associated with mortality …

Depression is common among people living with HIV/AIDS and contributes to a wide range
of worsened HIV-related outcomes, including AIDS-related mortality. Targeting modifiable …

Cryptococcal meningitis is common in sub-Saharan Africa. Given the need for data for a
rapid, point-of-care cryptococcal antigen (CRAG) lateral flow immunochromatographic assay (…

Background WHO recommends Xpert MTB/RIF as initial diagnostic testing for tuberculous
meningitis. However, diagnosis remains difficult, with Xpert sensitivity of about 50–70% and …

Background. Therapy for human immunodeficiency virus (HIV)–associated cryptococcal
meningitis in many centers in Africa is fluconazole administered at a dosage of 400–800 mg per …

Objectives: To assess whether T-cell activation independently predicts the extent of CD4+ T-cell
recovery and mortality in HIV-infected Ugandans initiating antiretroviral therapy (ART). …

Background . Progress in therapy for cryptococcal meningitis has been slow because of the
lack of a suitable marker of treatment response. Previously, we demonstrated the statistical …

Background HIV is highly stigmatized, compromising both treatment and prevention in
resource-limited settings. Purpose We sought to study the relationship between internalized HIV-…